Regeneron says its COVID-19 treatment reduces viral levels |
Clinical News
eMediNexus Coverage from: 
Regeneron says its COVID-19 treatment reduces viral levels

0 Read Comments                

Regeneron Pharmaceuticals Inc has stated that its experimental two-antibody cocktail reduced viral levels and improved symptoms among non-hospitalized COVID-19 patients, thus improving its odds of becoming a treatment for COVID-19 disease.

Regeneron Chief Scientific Officer, George Yancopoulos, stated that they hope that these data will support an emergency use authorization (EUA) from the U.S. Food and Drug Administration. The treatment, called REGN-COV2, is also under investigation for use in hospitalized patients, and for prevention of infection in individuals who have been exposed to COVID-19. The treatment could help patients whose own immune system is not strong enough to fight the virus, mentioned Regeneron… (ET Healthworld – Reuters, September 30, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now